Method for identifying kidney allograft recipients at risk for chronic injury

Patent metadata

Field	Value
Publication number	US-11674181-B2
Application number	US-202117164607-A
Country	US
Kind code	B2
Filing date	Feb 1, 2021
Priority date	Mar 12, 2014
Publication date	Jun 13, 2023
Grant date	Jun 13, 2023

Abstract

A method for identifying a renal allograft recipient at risk for chronic allograft damage or interstitial fibrosis and tubular atrophy (IF/TA) by comparing the transcription level of a preselected gene signature set with the transcription level of a comparison standard, and diagnosing the recipient as being at risk for chronic allograft damage if the transcription level of the preselected gene signature set is significantly higher than the transcription level of the comparison standard.

First claim

What is claimed is:

1. A method for treating a human renal allograft recipient at risk for chronic allograft damage or interstitial fibrosis and tubular atrophy (IF/TA) comprising the steps of:
(a) identifying a human renal allograft recipient as being at risk for chronic allograft damage or IF/TA upon detection of transcription levels in a tissue specimen from the renal allograft recipient of a preselected gene signature set which are higher than the transcription levels of the preselected gene signature set in a renal allograft tissue control sample obtained from a subject that did not develop chronic allograft damage or IF/TA, said transcription levels obtained by
i. synthesizing cDNA from mRNA isolated from a biopsy specimen obtained from said renal allograft recipient, and
ii. detecting the transcription levels of the preselected gene signature set in the cDNA, wherein said gene signature set comprises the genes KLHL13, KAAG1, MET, SPRY4, SERINC5, CHCHD10, FJX1, WNT9A, RNF149, ST5, TGIF1, RXRA and ASB15; and
(b) administering to the human renal allograft recipient having higher transcription levels of the preselected gene signature set an effective amount for treating chronic allograft damage, of an anti-fibrotic agent, an immunosuppressive agent, or both.

2. The method of claim 1 which comprises detecting the transcription levels of said preselected gene signature set of step (a) with RT-PCR analysis.

3. The method of claim 1 which comprises detecting the transcription levels of said preselected gene signature set of step (a) with Nanostring analysis.

4. The method of claim 1 which comprises detecting the transcription levels of said preselected gene signature set of step (a) with RNA SEQ analysis.

5. The method of claim 1 wherein said anti-fibrotic agent is selected from the group consisting of Pirfenidone, relaxin, Bone morphogenetic protein 7 (BMP-7) and Hepatic growth factor (HGF).

6. The method of claim 1 wherein said immunosuppressive agent is selected from the group consisting of a calcineurin inhibitor (CNI), prednisone, mycophenolate mofeti, belatacept, Mycophenolate Sodium and Azathioprine.

7. The method of claim 6 wherein the CNI is cyclosporine or tacrolimus.

8. The method of claim 1 wherein said renal allograft recipient is suffering from allograft rejection.

9. The method of claim 8 wherein said allograft recipient is suffering from acute cellular rejection.

10. The method of claim 8 wherein said allograft recipient is suffering from subcellular rejection.

11. The method of claim 1 which comprises detecting the transcription levels of said preselected gene signature set of step (a) with MiSeq analysis.

Assignees

• Icahn School Med Mount Sinai
• Western Sydney Local Health Distr

Inventors

• Murphy Barbara
• Zhang Weijia
• O'Connell Philip J

Classifications

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q2600/158

  Expression markers · CPC title